Top in hem/onc: T-cell therapy, multiple myeloma treatment
Click Here to Manage Email Alerts
The FDA has cleared an investigational new drug application for T-cell therapy to treat high-risk patients with COVID-19. It was the top story in hematology/oncology last week.
Additionally, the FDA granted priority review to idecabtagene vicleucel (Bristol Myers Squibb, bluebird bio) for the treatment of adults with relapsed or refractory advanced multiple myeloma.
Read these and more top stories in hematology/oncology below:
FDA clears IND application for T-cell therapy to treat high-risk patients with COVID-19
The FDA cleared an investigational new drug application for ALVR109 (AlloVir) for the treatment of high-risk adults with COVID-19 infection, according to the agent’s manufacturer. Read more.
FDA grants priority review to idecabtagene vicleucel for advanced multiple myeloma
The FDA granted priority review to idecabtagene vicleucel for the treatment of certain adults with relapsed or refractory multiple myeloma, according to the agent’s developers. Read more.
Fauci ‘cautiously optimistic’ about identifying effective COVID-19 vaccine by end of 2020
An effective vaccine for the novel coronavirus likely will be identified in the next few months, the nation’s leading infectious disease expert told ESMO Virtual Congress 2020 attendees. Read more.
Sacituzumab govitecan improves survival in pretreated triple-negative breast cancer
Sacituzumab govitecan (Trodelvy, Immunomedics) significantly improved progression-free survival and overall survival compared with single-agent chemotherapy among patients with pretreated metastatic triple-negative breast cancer, according to findings presented during ESMO Virtual Congress 2020. Read more.
Pembrolizumab regimen superior to chemotherapy alone in advanced esophageal cancer
The addition of pembrolizumab (Keytruda, Merck) to chemotherapy improved overall survival, progression-free survival and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results of the phase 3 KEYNOTE-590 study showed. Read more.